Marek Trněný | Riziko histologické transformace u nemocných s FL - retrospektivní analýza
A question of age: how should elderly DLBCL patients be treated?
Marek Trněný | Retrospective CLSG analysis on biopsy-proven FL transformation in the rituximab era
ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trneny | Was the PRIMA PI prognostic index feasible in a real-world cohort of FL patients?
Results of Phase III GADOLIN trial for follicular lymphoma
AUGMENT: Is the combination of lenalidomide & rituximab efficacious in elderly patients with iNHL?
iwNHL 2017 highlights: the PDX model
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Message to mantle cell lymphoma physicians and patients
Phase II study of Lenalidomide Vs Best Investigator’s in Choice Relapsed/Refractory MCL
Prof. Marek Trněný | ASH 2017 | R-CHOP plus rituximab maintenance in elderly patients
Prof. Marek Trněný discusses highlights from 13-ICML 2015
Karolína, pacientka s vyléčeným Hodgkinovým lymfomem - Můžete porovnat různé typy léčby?
Prof. Marek Trněný: Update on the GOYA study – ICML 2017
Prof. Marek Trněný on his research on mantle cell lymphoma
Protonové Centrum - Řekli to za nás
Prof. Marek Trněný: Highlights of Mantle Cell Lymphoma - ICML 2017
"Nikdy to nevzdávej!"
